Drug profile · INN
methscopolamine bromide
METHSCOPOLAMINE BROMIDE
methscopolamine bromide (METHSCOPOLAMINE BROMIDE) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — methscopolamine bromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 2
- Data quality
- 0.84
Quick answer
methscopolamine bromide (METHSCOPOLAMINE BROMIDE) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12162861
Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
granted -
US 12145922
Selective D3 dopamine receptor agonists and methods of their use
granted -
US 12102640
Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
granted -
US 12097196
Dopamine D3 receptor selective antagonists/partial agonists and uses thereof
granted -
US 11634404
Selective D3 dopamine receptor agonists and methods of their use
granted -
US 11337971
Dopamine D3 receptor selective antagonists/partial agonists and uses thereof
granted -
US 11299476
Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
granted -
US 11261461
Methods and compositions for selective generation of dopaminergic precursors
granted -
US 11033554
Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
CA 3142348
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
US 10654842
Dopamine D3 receptor antagonist compounds
granted -
US 10577361
Dopamine D3 receptor antagonists having a morpholine moiety
granted -
CA 3103212
FORMULATIONS COMPRENANT DES INHIBITEURS DE LA DOPAMINE-S-HYDROXYLASE ET LEURS PROCEDES DE PREPARATION
granted -
US 2019337950
BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS
granted -
CA 3082337
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
US 10273244
Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
granted -
US 10239870
Dopamine D3 receptor antagonists
granted -
US 10016499
Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
granted
Frequently asked questions
What is methscopolamine bromide?
methscopolamine bromide (METHSCOPOLAMINE BROMIDE) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for methscopolamine bromide?
METHSCOPOLAMINE BROMIDE is a marketed brand name for methscopolamine bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methscopolamine bromide?
methscopolamine bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.